Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Concentrated Growth Factors for Spinal Cord Injury
NCT07253233Phase 1Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Adoptive Cell Transfer
01
Overview
Phase 1, open-label, single-arm trial of concentrated growth factor in spinal cord injury (SCI), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Change in ASIA Motor Score at 12 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
concentrated growth factor
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT07253233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253233.